A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

This study has been terminated.
(The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00996918
First received: October 14, 2009
Last updated: November 12, 2013
Last verified: November 2013
Results First Received: November 12, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg
Drug: Bapineuzumab 1.0 m/kg

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This extension study was conducted at 91 centers in 17 countries. The study was terminated early by the sponsor on 06 August 2012. Participants who had not completed the final follow-up visit prior to 06 August 2012 were asked to complete an early termination visit.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants who had completed the base study protocol 3133K1-3000 were allowed to participate in this extension study. Participants who developed vasogenic edema during study 3133K1-3000 were considered for study 3133K1-3002 participation if the abnormality was resolved and the participant met criteria to resume the investigational product.

Reporting Groups
  Description
Placebo/Bapineuzumab 0.5 Milligram/Kilogram(mg/kg) Participants received placebo in the base study and 0.5 mg/kg bapineuzumab in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg Participants received 0.5 mg/kg bapineuzumab in both the base and extension studies. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Placebo/Bapineuzumab 1.0 mg/kg Participants received placebo in the base study and 1.0 mg/kg bapineuzumab in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 1.0 mg/kg/Bapineuzumab 1.0 mg/kg Participants received 1.0 mg/kg bapineuzumab in both the base and extension studies. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 2.0 mg/kg/ Bapineuzumab 1.0 mg/kg Participants originally randomized to 2.0 mg/kg bapineuzumab were reassigned to the 1.0 mg/kg dose level after discontinuation of 2.0 mg/kg dose level in the base study and continued the 1.0 mg/kg dose in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.

Participant Flow:   Overall Study
    Placebo/Bapineuzumab 0.5 Milligram/Kilogram(mg/kg)     Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg     Placebo/Bapineuzumab 1.0 mg/kg     Bapineuzumab 1.0 mg/kg/Bapineuzumab 1.0 mg/kg     Bapineuzumab 2.0 mg/kg/ Bapineuzumab 1.0 mg/kg  
STARTED     39     66     37     56     4  
Treated     39     66     37     56     4  
COMPLETED     0     0     0     0     0  
NOT COMPLETED     39     66     37     56     4  
Lack of Efficacy                 1                 1                 2                 2                 0  
Adverse Event                 2                 5                 2                 6                 0  
Withdrawal by Subject                 1                 4                 3                 3                 2  
Physician Decision                 1                 0                 0                 0                 0  
Discontinuation of Study by Sponsor                 31                 54                 30                 45                 2  
Loss of Caregiver                 0                 1                 0                 0                 0  
Not Specified                 3                 1                 0                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo/Bapineuzumab 0.5 mg/kg Participants received placebo in the base study and 0.5 mg/kg bapineuzumab in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg Participants received 0.5 mg/kg bapineuzumab in both the base and extension studies. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Placebo/Bapineuzumab 1.0 mg/kg Participants received placebo in the base study and 1.0 mg/kg bapineuzumab in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 1.0 mg/kg/Bapineuzumab 1.0 mg/kg Participants received 1.0 mg/kg bapineuzumab in both the base and extension studies. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 2.0 mg/kg/Bapineuzumab 1.0 mg/kg Participants originally randomized to 2.0 mg/kg bapineuzumab were reassigned to the 1.0 mg/kg dose level after discontinuation of 2.0 mg/kg dose level in the base study and continued the 1.0 mg/kg dose in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Total Total of all reporting groups

Baseline Measures
    Placebo/Bapineuzumab 0.5 mg/kg     Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg     Placebo/Bapineuzumab 1.0 mg/kg     Bapineuzumab 1.0 mg/kg/Bapineuzumab 1.0 mg/kg     Bapineuzumab 2.0 mg/kg/Bapineuzumab 1.0 mg/kg     Total  
Number of Participants  
[units: participants]
  38     62     33     53     4     190  
Age  
[units: Years]
Mean ± Standard Deviation
  68.9  ± 9.70     71.9  ± 8.83     68.8  ± 8.59     70.6  ± 9.13     71.3  ± 10.63     70.4  ± 9.08  
Age, Customized  
[units: Number of participants]
           
< 65     17     15     12     17     1     62  
>= 65     21     47     21     36     3     128  
Gender  
[units: Number of participants]
           
Female     13     28     14     19     3     77  
Male     25     34     19     34     1     113  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Reporting a Serious Adverse Event.   [ Time Frame: Up to Week 195 ]

2.  Secondary:   Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.   [ Time Frame: Weeks 13, 26, 39, 52 and 78 ]

3.  Secondary:   Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.   [ Time Frame: Weeks 13, 26, 39, 52 and 78 ]

4.  Secondary:   Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.   [ Time Frame: Weeks 13, 26, 39, 52 and 78 ]

5.  Secondary:   Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78   [ Time Frame: Weeks 13, 26, 39, 52 and 78 ]

6.  Secondary:   Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.   [ Time Frame: Weeks 26, 52 and 78 ]

7.  Secondary:   Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.   [ Time Frame: Weeks 26, 52 and 78 ]

8.  Secondary:   Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.   [ Time Frame: Weeks 6, 19, 32, 45 and 78 ]

9.  Secondary:   Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.   [ Time Frame: Weeks 6, 19, 32, 45 and 78 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame 2.6 years
Additional Description The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.

Reporting Groups
  Description
Placebo/Bapineuzumab 0.5 mg/kg Participants received placebo in the base study and 0.5 mg/kg bapineuzumab in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg Participants received 0.5 mg/kg bapineuzumab in both the base and extension studies. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Placebo/Bapineuzumab 1.0 mg/kg Participants received placebo in the base study and 1.0 mg/kg bapineuzumab in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 1.0 mg/kg/Bapineuzumab 1.0 mg/kg Participants received 1.0 mg/kg bapineuzumab in both the base and extension studies. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.
Bapineuzumab 2.0 mg/kg/Bapineuzumab 1.0 mg/kg Participants originally randomized to 2.0 mg/kg bapineuzumab were reassigned to the 1.0 mg/kg dose level after discontinuation of 2.0 mg/kg dose level in the base study and continued the 1.0 mg/kg dose in this extension study. In this extension study bapineuzumab was administered by IV infusion approximately every 13 weeks up to Week 195.

Serious Adverse Events
    Placebo/Bapineuzumab 0.5 mg/kg     Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg     Placebo/Bapineuzumab 1.0 mg/kg     Bapineuzumab 1.0 mg/kg/Bapineuzumab 1.0 mg/kg     Bapineuzumab 2.0 mg/kg/Bapineuzumab 1.0 mg/kg  
Total, serious adverse events            
# participants affected / at risk     6/39 (15.38%)     10/66 (15.15%)     1/37 (2.70%)     11/56 (19.64%)     0/4 (0.00%)  
Cardiac disorders            
Myocardial infarction * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Gastrointestinal disorders            
Large intestine perforation * 1          
# participants affected / at risk     1/39 (2.56%)     0/66 (0.00%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     1     0     0     0     0  
General disorders            
Chest pain * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     2     0  
Injury, poisoning and procedural complications            
Chest injury * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Fall * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Femur fracture * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Hip fracture * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Skull fracture * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Subdural haematoma * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     3/56 (5.36%)     0/4 (0.00%)  
# events     0     0     0     3     0  
Musculoskeletal and connective tissue disorders            
Polymyalgia rheumatica * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Rhabdomyolysis * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)            
Basal cell carcinoma * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Bladder cancer * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Metastatic squamous cell carcinoma * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Pancreatic neoplasm * 1          
# participants affected / at risk     1/39 (2.56%)     0/66 (0.00%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     1     0     0     0     0  
Nervous system disorders            
Cerebellar infarction * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Dementia * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Epilepsy * 1          
# participants affected / at risk     1/39 (2.56%)     0/66 (0.00%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     1     0     0     0     0  
Ischaemic stroke * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     1     0     1     0  
Loss of consciousness * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Partial seizures with secondary generalisation * 1          
# participants affected / at risk     1/39 (2.56%)     0/66 (0.00%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     1     0     0     0     0  
Subarachnoid haemorrhage * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Vasogenic cerebral oedema * 1          
# participants affected / at risk     1/39 (2.56%)     0/66 (0.00%)     1/37 (2.70%)     0/56 (0.00%)     0/4 (0.00%)  
# events     1     0     1     0     0  
Psychiatric disorders            
Disorientation * 1          
# participants affected / at risk     1/39 (2.56%)     0/66 (0.00%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     1     0     0     0     0  
Suicidal ideation * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
Respiratory, thoracic and mediastinal disorders            
Pulmonary embolism * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Vascular disorders            
Deep vein thrombosis * 1          
# participants affected / at risk     0/39 (0.00%)     1/66 (1.52%)     0/37 (0.00%)     0/56 (0.00%)     0/4 (0.00%)  
# events     0     1     0     0     0  
Phlebitis * 1          
# participants affected / at risk     0/39 (0.00%)     0/66 (0.00%)     0/37 (0.00%)     1/56 (1.79%)     0/4 (0.00%)  
# events     0     0     0     1     0  
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 15.0




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.


  More Information